BIAL, a hundred-year-old innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, announced that the first patient has completed the full dose regimen in the ACTIVATE ...

Breakthroughs in laboratory and data science are increasing interest in blood tests to screen for cancer, with colorectal ...

Results from a study called Mariposa found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced ...

More than 66,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.

We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.